Martin Avenue Pharmacy Recalls Testosterone Cypionate Injection Due to Sterility Concerns
Martin Avenue Pharmacy is voluntarily recalling Testosterone cypionate 250 mg/mL injections due to quality control issues that may compromise sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves a risk to sterility assurance, which aligns with the rubric criteria for Severe severity (FDA Class II with potential for significant health consequences).
Plain-English summary
Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of Testosterone cypionate 250 mg/mL injections packaged in amber glass vials. The recall covers all compounded sterile preparations within their expiry date. The specific lot number is 08012014@34, with an expiration date of 10/30/2014.
The recall was initiated following a recent FDA inspection that identified observations associated with certain quality control procedures. These issues present a risk to the assurance of sterility for the compounded preparations. The agency has classified this recall as Class II.
The affected products were distributed nationwide. Consumers and healthcare providers should check their inventory for the specific lot number and expiration date listed above. If the product matches the recalled lot, it should be discontinued and returned to the pharmacy or disposed of according to local regulations.
The recalled product
- Product
- Testosterone cypionate 250 mg/mL injection packaged in an amber glass injectable vial, Martin Avenue Pharmacy, 1247 Rickert Dr, Naperville, IL.
- Manufacturer
- Martin Avenue Pharmacy, Inc.
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot Number: 08012014@34
- Exp 10/30/2014
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 118 recalled by Martin Avenue Pharmacy, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 118 products in this recall →Related recalls
Same manufacturer · Martin Avenue Pharmacy, Inc.
See all →- SevereMartin Avenue Pharmacy Recalls Atropine Sulfate Eye Drops for Sterility Concerns
FDA (Drugs) · 2014-11-05
- SevereMartin Avenue Pharmacy Recalls Compounded Sterile Preparations Due to Sterility Concerns
FDA (Drugs) · 2014-11-05
- SevereMartin Avenue Pharmacy Recalls Compounded Hydromorphone and Bupivacaine Injections
FDA (Drugs) · 2014-11-05
- HighMartin Avenue Pharmacy Recalls Tri-mix T50 Injectable Due to Sterility Concerns
FDA (Drugs) · 2014-11-05
- HighMartin Avenue Pharmacy Recalls Tri-mix ST2 Injectable Due to Sterility Concerns
FDA (Drugs) · 2014-11-05
Same hazard · sterility risk
See all →- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Vancomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereFDA Recalls Rohto Dry-Aid Eye Drops Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighMedline Medical Procedure Kits Recalled for High Endotoxin Levels
FDA (Devices) · 2026-05-06
- HighCook Medical tracheostomy introducer sets labeled with overstated expiration dates
FDA (Devices) · 2026-04-15
Similar recalls
- SevereTestosterone Cypionate Injection Recalled Due to Sterility Concerns
FDA (Drugs) · 2015-09-23
- SevereTestosterone Cypionate Injection Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
- SevereAnderson Compounding Pharmacy Recalls Testosterone Cypionate Injection Due to Sterility Concerns
FDA (Drugs) · 2019-04-24
- SevereTestosterone Cypionate Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
- SevereTestosterone Cypionate Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2015-09-23
- SevereTestosterone Cypionate Injectable Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2021-11-17